Keros Therapeutics Chief Financial Officer Keith Regnante has resigned from his position, effective Aug. 3. The company has named Annita Tanini, Vice President of Finance, as the interim principal financial officer to ensure continuity in its financial operations during the transition period.

Leadership Transition Details

The departure of Regnante and the subsequent appointment of Tanini were formalized through a regulatory filing submitted to the Securities and Exchange Commission (SEC). The document outlines the specific timeline for the leadership change, confirming that the resignation takes effect on the stated date in August.

Interim Appointment

Annita Tanini will assume the responsibilities of the principal financial officer on an interim basis. While the filing confirms the immediate change in role, it does not specify the duration of the interim period or provide details regarding a search for a permanent successor to the CFO position.

Keros Therapeutics, Inc. has appointed Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. The addition of Prener aims to strengthen the company's clinical development expertise and executive leadership as it advances its pipeline of novel therapeutics targeting disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.

Jean-Jacques Bienaimé, Chair of the Board of Directors, stated that Prener's combination of clinical development expertise and executive leadership experience will be invaluable for executing the company's corporate strategy. He emphasized that her perspective will be instrumental in supporting the company for long-term growth and value creation.

Prener currently serves as a Senior Innovation Advisor at the University of Copenhagen and as a non-executive director of the board of XSpray Pharma. Her previous roles include Chief Executive Officer of Imbria Pharmaceuticals Inc. from July 2020 until September 2024 and venture partner at SV Health Investors from September 2020 until October 2024. She also served as Chief Executive Officer of Freeline Therapeutics Ltd. from July 2017 to June 2019 and Chief Executive Officer of Gyroscope Therapeutics Ltd. from August 2016 until July 2017.

Earlier in her career, Prener held leadership positions at Baxalta as Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology. She also served as Senior Vice President, Hemophilia R&D Portfolio at Novo Nordisk. Prener has previously served on the boards of directors of Galecto, Inc., Rubius Therapeutics, Inc., and Kaleido Biosciences, Inc.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company's lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced product candidate, elritercept, is being developed for the treatment of cytopenias in patients with myelodysplastic syndrome and myelofibrosis.